ONO-8430506 | CAS#1354805-08-5 | ENPP2 inhibitor

MedKoo Cat#: 462074 | Name: ONO-8430506

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ONO-8430506 is a potent autotaxin inhibitor that enhances the antitumor effect of paclitaxel in a breast cancer model. Lysophosphatidic acid (LPA) is a bioactive lipid mediator that elicits a number of biological functions, including smooth muscle contraction, cell motility, proliferation, and morphological change. LPA is endogenously produced by autotaxin (ATX) from extracellular lysophosphatidylcholine (LPC) in plasma.

Chemical Structure

ONO-8430506

CAS#1354805-08-5

Theoretical Analysis

MedKoo Cat#: 462074

Name: ONO-8430506

CAS#: 1354805-08-5

Chemical Formula: C27H28FN3O3

Exact Mass: 461.2115

Molecular Weight: 461.54

Elemental Analysis: C, 70.26; H, 6.12; F, 4.12; N, 9.10; O, 10.40

Price and Availability

Size	Price	Availability
5mg	USD 950.00	2 Weeks
10mg	USD 1,650.00	2 Weeks
25mg	USD 2,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ONO-8430506; ONO 8430506; ONO8430506

IUPAC/Chemical Name

4-(2-(9-(4-fluorobenzyl)-5,6,8,9-tetrahydro-7H-pyrrolo[2,3-b:5,4-c']dipyridin-7-yl)-2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylic acid

InChi Key

SGSFONPFVRRJLS-UHFFFAOYSA-N

InChi Code

InChI=1S/C27H28FN3O3/c28-19-5-3-18(4-6-19)15-31-22-16-30(13-7-20(22)21-2-1-12-29-24(21)31)23(32)14-26-8-10-27(17-26,11-9-26)25(33)34/h1-6,12H,7-11,13-17H2,(H,33,34)

SMILES Code

O=C(C1(C2)CCC2(CC(N(C3)CCC4=C3N(CC5=CC=C(F)C=C5)C6=NC=CC=C64)=O)CC1)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 461.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ebrahimi E, Wuest M, Kaur J, Bhardwaj A, Gade NR, Wuest F. [¹⁸F]ONO-8430506: A novel radioligand for PET imaging of autotaxin (ATX). Bioorg Med Chem Lett. 2023 Jun 15;90:129345. doi: 10.1016/j.bmcl.2023.129345. Epub 2023 May 20. PMID: 37217023. 2: Iwaki Y, Ohhata A, Nakatani S, Hisaichi K, Okabe Y, Hiramatsu A, Watanabe T, Yamamoto S, Nishiyama T, Kobayashi J, Hirooka Y, Moriguchi H, Maeda T, Katoh M, Komichi Y, Ota H, Matsumura N, Okada M, Sugiyama T, Saga H, Imagawa A. ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. ACS Med Chem Lett. 2020 May 14;11(6):1335-1341. doi: 10.1021/acsmedchemlett.0c00200. PMID: 32551021; PMCID: PMC7294725. 3: Benesch MG, Tang X, Maeda T, Ohhata A, Zhao YY, Kok BP, Dewald J, Hitt M, Curtis JM, McMullen TP, Brindley DN. Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. FASEB J. 2014 Jun;28(6):2655-66. doi: 10.1096/fj.13-248641. Epub 2014 Mar 5. PMID: 24599971. 4: Uranbileg B, Ito N, Kurano M, Kano K, Uchida K, Sumitani M, Aoki J, Yatomi Y. Inhibition of autotaxin activity ameliorates neuropathic pain derived from lumbar spinal canal stenosis. Sci Rep. 2021 Feb 17;11(1):3984. doi: 10.1038/s41598-021-83569-3. PMID: 33597645; PMCID: PMC7889906. 5: Aikawa S, Kano K, Inoue A, Aoki J. Proliferation of mouse endometrial stromal cells in culture is highly sensitive to lysophosphatidic acid signaling. Biochem Biophys Res Commun. 2017 Feb 26;484(1):202-208. doi: 10.1016/j.bbrc.2016.12.154. Epub 2017 Jan 7. PMID: 28073697. 6: Benesch MG, Zhao YY, Curtis JM, McMullen TP, Brindley DN. Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate. J Lipid Res. 2015 Jun;56(6):1134-44. doi: 10.1194/jlr.M057661. Epub 2015 Apr 20. PMID: 25896349; PMCID: PMC4442871. 7: Benesch MG, Ko YM, Tang X, Dewald J, Lopez-Campistrous A, Zhao YY, Lai R, Curtis JM, Brindley DN, McMullen TP. Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer. Endocr Relat Cancer. 2015 Aug;22(4):593-607. doi: 10.1530/ERC-15-0045. Epub 2015 Jun 2. PMID: 26037280. 8: Benesch MG, Tang X, Dewald J, Dong WF, Mackey JR, Hemmings DG, McMullen TP, Brindley DN. Tumor-induced inflammation in mammary adipose tissue stimulates a vicious cycle of autotaxin expression and breast cancer progression. FASEB J. 2015 Sep;29(9):3990-4000. doi: 10.1096/fj.15-274480. Epub 2015 Jun 12. PMID: 26071407. 9: Venkatraman G, Benesch MG, Tang X, Dewald J, McMullen TP, Brindley DN. Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment. FASEB J. 2015 Mar;29(3):772-85. doi: 10.1096/fj.14-262659. Epub 2014 Nov 14. PMID: 25398768. 10: Saga H, Ohhata A, Hayashi A, Katoh M, Maeda T, Mizuno H, Takada Y, Komichi Y, Ota H, Matsumura N, Shibaya M, Sugiyama T, Nakade S, Kishikawa K. A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension. PLoS One. 2014 Apr 18;9(4):e93230. doi: 10.1371/journal.pone.0093230. PMID: 24747415; PMCID: PMC3991570.